NeuroVive Admitted To Trading On NASDAQ OMX Stockholm
LUND, Sweden, March 25, 2013 /PRNewswire/ --
NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th.
The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in conjunction with the listing on NASDAQ OMX Stockholm.
Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: "Our move to NASDAQ OMX Stockholm is an important step forward in the growth and development of our company. Through this listing NeuroVive will gain access to a broader and deeper pool of investors that will be vital as we look to finance our strategy which is designed to maximize shareholder value from our leading position in mitochondrial medicine."About NeuroVive Pharmaceutical AB (publ) NeuroVive Pharmaceutical AB ( http://www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. NeuroVive's products are based on the cyclophilin inhibitor, cyclosporine, and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury. NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following cardiac stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction. NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts